{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:07:52Z","timestamp":1783908472350,"version":"3.55.0"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The glycoengineered humanized monoclonal type II anti-CD20 antibody obinutuzumab is widely used in the treatment of patients with chronic lymphocytic leukemia (CLL), most commonly in combination with other therapeutic agents.<\/jats:p>\n                  <jats:p>The aim of this single-centre retrospective study was to evaluate the treatment patterns and clinical responses in patients with CLL treated with obinutuzumab-based combination regimens at the University Clinic of Hematology, Skopje.<\/jats:p>\n                  <jats:p>We analyzed 90 patients with CLL treated with obinutuzumab-based regimens between 2019 and 2024. Obinutuzumab was administered in combination with chlorambucil (56.6%), fludarabine\u2013cyclophosphamide (26.6%), bendamustine (11.1%), CVP (4.4%), or venetoclax (5.5%). The treatment was given as first-line therapy in 57.7% of patients and in the relapsed\/refractory setting in 42.3%.<\/jats:p>\n                  <jats:p>The median age at initiation of obinutuzumab-based therapy was 66.9 years. The overall response rate to obinutuzumab-based treatment was 45.5%. The median follow-up after treatment was 15.6 months.<\/jats:p>\n                  <jats:p>In this real-world single-centre experience, obinutuzumab-based combination regimens showed measurable clinical activity in routine practice across different treatment lines. Longer follow-up and larger patient cohorts are required to better characterize the durability of the responses and outcomes in the specific treatment subgroups.<\/jats:p>","DOI":"10.2478\/prilozi-2026-0010","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:07:54Z","timestamp":1774080474000},"page":"93-100","source":"Crossref","is-referenced-by-count":0,"title":["Response Rate in CLL Patients Treated with Obinutuzumab - Single Centre Experience from University Clinic of Hematology, Skopje"],"prefix":"10.2478","volume":"47","author":[{"given":"Olivera Gjeorgjieva","family":"Janev","sequence":"first","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Mojsovska","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stojanoski","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Pavkovic","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija Popova","family":"Labachevska","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazar","family":"Chadievski","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra Pivkova","family":"Veljanovska","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlate","family":"Stojanoski","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja Genadieva","family":"Stavrikj","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology, Medical Faculty , University Ss. Cyril and Methodius , Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"2026071216021759609_j_prilozi-2026-0010_ref_001","doi-asserted-by":"crossref","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le D\u00fb K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056\/NEJMoa1815281. Epub 2019 Jun 4. PMID: 31166681.","DOI":"10.1056\/NEJMoa1815281"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_002","doi-asserted-by":"crossref","unstructured":"Moia R, Gaidano G. Prognostication in chronic lymphocytic leukemia. Semin Hematol. 2024 Apr;61(2):83-90. doi: 10.1053\/j.seminhematol.2024.02.002. Epub 2024 Mar 1. PMID: 38523019.","DOI":"10.1053\/j.seminhematol.2024.02.002"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_003","doi-asserted-by":"crossref","unstructured":"Rossi D., Rasi S., Spina V., Bruscaggin A., Monti S., Ciardullo C., Deambrogi C., Khiabanian H., Serra R., Bertoni F., et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121:1403\u20131412. doi: 10.1182\/blood-2012-09-458265.","DOI":"10.1182\/blood-2012-09-458265"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_004","doi-asserted-by":"crossref","unstructured":"Pedro Horna, Kathryn E. Pearce, Rhett P. Ketterling, Jess Peterson. Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma\/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections, Blood. Volume 134, Supplement 1, 2019. Page 4282. ISSN 0006-4971. https:\/\/doi.org\/10.1182\/blood-2019-129116.","DOI":"10.1182\/blood-2019-129116"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_005","doi-asserted-by":"crossref","unstructured":"Alexandre Bazinet, Ryan N Rys, Claudia M Wever, Amadou Barry, Celia Green-wood, Christian Young, Alma Mendoza, Ida LaPorta, Sylvain Gimmig, Fran\u00e7ois Mercier, Nathalie Johnson; A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia. Blood 2019; 134 (Supplement_1): 5451. doi: https:\/\/doi.org\/10.1182\/blood-2019-123904.","DOI":"10.1182\/blood-2019-123904"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_006","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V. Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des Devel Ther. 2017 Jan 25; 11:295-304. doi: 10.2147\/DDDT.S104869. PMID: 28182141; PMCID: PMC5279834.","DOI":"10.2147\/DDDT.S104869"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_007","doi-asserted-by":"crossref","unstructured":"Leblond V, Aktan M, Ferra Coll CM, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot JL, Robson S, Gresko E, Bosch F, Stilgenbauer S, Fo\u00e0 R. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed\/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324\/haematol.2017.186387. Epub 2018 Jul 5. PMID: 29976743; PMCID: PMC6278964.","DOI":"10.3324\/haematol.2017.186387"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_008","doi-asserted-by":"crossref","unstructured":"Ciara L. Freeman, Franck Morschhauser, Laurie Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, G\u00fcnter Fingerle-Rowson, Elisabeth Wassner-Fritsch, John G. Gribben, Michael Hallek, Gilles Salles, Guillaume Cartron; Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood 2015; 126 (24): 2646\u20132649. doi: https:\/\/doi.org\/10.1182\/blood-2015-09-670802.","DOI":"10.1182\/blood-2015-09-670802"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_009","doi-asserted-by":"crossref","unstructured":"Braish J, Cerchione C, Ferrajoli A. An overview of prognostic markers in patients with CLL. Front Oncol. 2024 May 16;14:1371057. doi: 10.3389\/fonc.2024.1371057. PMID: 38817892; PMCID: PMC11137234.","DOI":"10.3389\/fonc.2024.1371057"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_010","unstructured":"Marshall A. Lichtman et al. Williams Manual Of Hematology tenth edition. Part VIII, The Clonal Lymphoid and Plasma Cell Diseases, page 390, 395."},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_011","doi-asserted-by":"crossref","unstructured":"Pirich T, Zwickl-Traxler E, Pecherstorfer M, Singer J. Tolerability of obinutuzumab therapy in patients with rituximab-relapsed\/refractory B-cell malignancies - a retrospective single center cohort study. Oncotarget. 2018 Jul 6;9(52):29944-29956. doi: 10.18632\/oncotarget.25714. PMID: 30042825; PMCID: PMC6057460.","DOI":"10.18632\/oncotarget.25714"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_012","doi-asserted-by":"crossref","unstructured":"Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, Bowen DA, Conte M, Jelinek DF, Slager SL, Shanafelt TD. Chronic lymphocytic leukemia in young (\u2264 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014 Jan;99(1):140-7. doi: 10.3324\/haematol.2013.086066. Epub 2013 Aug 2. PMID: 23911703; PMCID: PMC4007929.","DOI":"10.3324\/haematol.2013.086066"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_013","doi-asserted-by":"crossref","unstructured":"Palaian S, Ibrahim MIM, Mishra P et al. Assessment of a Pharmacovigilance Module: An Interventional Study on Knowledge, Attitude, and Practice of Pharmacy Students. J. pharm. bioallied sci. 2021; 13(2):248-255.","DOI":"10.4103\/jpbs.JPBS_528_20"},{"key":"2026071216021759609_j_prilozi-2026-0010_ref_014","doi-asserted-by":"crossref","unstructured":"Panneerselvam N, Kathirvelu P, Manoharan R. Impact of educational intervention on the knowledge, attitude, and practice of pharmacovigilance among postgraduates of a tertiary care center, Kanchipuram, Tamil Nadu, India. Perspect Clin Res. 2022;13(4):199-204.","DOI":"10.4103\/picr.PICR_239_20"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2026-0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:33:37Z","timestamp":1783906417000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2026-0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,21]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/prilozi-2026-0010"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2026-0010","relation":{},"ISSN":["1857-8985"],"issn-type":[{"value":"1857-8985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}